

Data Use Agreement for

“Using California Breast Cancer Registry Data with Synthetic Census Tracts”

The Synthetic California Breast Cancer Registry Data (SynCan) is a pilot data product of the National Cancer Institute (NCI)’s Surveillance, Epidemiology, and End Results (SEER) Program (<https://seer.cancer.gov/>). SynCan contains all demographic and clinical information on malignant female breast cancers that are currently released as part of SEER’s research database (<https://seer.cancer.gov/data-software/documentation/seerstat/nov2018/>) and five synthetic census tracts that were generated using classification and regression tree models, plus census-tract level ecologic variables linked based on synthetic census tracts.

Researchers who wish to be granted access to the SynCan to explore analyses, and to have his/her final analyses validated by the NCI using the actual data, agree to and acknowledge the following:

1. Patient confidentiality is of the utmost importance in using the data, and all data that may lead to re-identification of any patient, physician, or reporting facility is strictly confidential.
2. All actual data outputs are subject to confidentiality review prior to being returned to the Researcher. Many factors are considered in the confidentiality review. As a general guideline, no rates should be reported for populations less than 20,000 person-years, and tables with cell size less than 5 should be suppressed.
3. The Researcher is expected to provide sufficient comments within the codes to describe the purpose of each key step in the analyses.
4. The Researcher is expected to exercise due diligence to ensure that the codes submitted for the final analyses are fully debugged and can be executed without errors using the actual data.
5. The NCI reserves the right to reject programming codes and/or terminate the study if the codes cannot be executed after reasonable accommodations.
6. The NCI has the Researcher’s permission to submit comparisons of synthetic data results and actual data results of the Researcher’s final analyses for publication consideration after December 31, 2021, or 18 months after the award.

My signature indicates that I agree to comply with the above stated provisions.

Print Name: _____

Address: _____

Email address: _____ Phone: _____

Signature: _____ Date: _____